

Xencor, Inc. Investor Relations Department 111 West Lemon Avenue Monrovia, CA 91016 United States

Visit IR website ☐ Sign-up for Email alerts ☐

NASDAQ: XNCR Last Trade: 21.85 Trade Time: 4:00 PM ET Sep 22, 2017 Change: 0.00 (0.000%) Day Range N/A - N/A 52-Week Range 18.45 - 29.38 Volume N/A

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Since Xencor's founding in 1997, investors have been drawn to our remarkable scientific capabilities around monoclonal antibodies and solid intellectual property which serve as the engine behind our drug development programs. Currently, 11 candidates that have been engineered with Xencor's XmAb® technology are in clinical development by us or with partners. Xencor's internal programs include: XmAb®5871 in Phase 2 development for the treatment of IgG4-Related Disease, and also for the treatment of Systemic Lupus Erythematosus; XmAb®7195 in Phase 1a development fo... (more)

Stock Performance



Press Releases [View all]

Sep 20, 2017

Xencor to Present at Upcoming Investor Conferences

Aug 7, 2017

Xencor Reports Second Quarter 2017 Financial Results

Aug 2, 2017

Xencor to Present at Upcoming Investor Conferences

Jul 31, 2017

Xencor to Host Second Quarter 2017
Financial Results Webcast and Conference
Call on August 7, 2017

Jun 16, 2017

Xencor Presents Interim Data from an Ongoing, Open-label, Phase 2 Study of XmAb®5871 in IgG4-Related Disease at EULAR 2017

Upcoming Events [View all]

Sep 27, 2017

Cantor Fitzgerald Global Healthcare Conference

Sep 28, 2017

<u>Leerink Partners Roundtable Series: Rare</u> <u>Disease & Immuno-Oncology</u>

Financials [View all]

Second Quarter Financial Results

Mar 1, 2017

Annual Report (10-K)

May 1, 2017

Proxy Statement (DEF 14A)

Aug 7, 2017

Quarterly Report (10-Q)

May 10, 2017

Quarterly Report (10-Q)

Nov 2, 2016

Quarterly Report (10-Q)